Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sulfamerazine is a small molecule sulfonamide antibiotic used primarily for the treatment of various bacterial infections, including bronchitis, prostatitis, and urinary tract infections. It acts as a bacteriostatic agent by inhibiting the bacterial enzyme dihydropteroate synthase (also known as dihydrofolate synthetase), which is essential for folic acid synthesis in bacteria. By competing with para-aminobenzoic acid (PABA) for binding to this enzyme, sulfamerazine disrupts the production of dihydrofolic acid and subsequently impairs nucleic acid and DNA synthesis in susceptible organisms. Sulfamerazine has been approved for both human and veterinary use but is no longer available for human use in some regions such as the United States[1][2][5][6][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sulfamerazine.